应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SHWGY 威高股份ADR
交易中 12-17 14:30:00 EST 延时
资讯
新帖
简况
中泰国际:予威高股份“增持”评级 目标价5.94港元
智通财经网 · 11-12
中泰国际:予威高股份“增持”评级 目标价5.94港元
大健康行业周报 |瑞普生物:1.54亿元加码宠物产业链布局;123亿,中东资本押注中国医械公司
保观 · 10-20
大健康行业周报 |瑞普生物:1.54亿元加码宠物产业链布局;123亿,中东资本押注中国医械公司
威高股份将于8月27日举行董事会会议以审批中期业绩
格隆汇资讯 · 08-07
威高股份将于8月27日举行董事会会议以审批中期业绩
暂无数据
公司概况
公司名称:
威高股份ADR
所属市场:
PINK LIMITED
上市日期:
--
主营业务:
山东威高集团医用高分子制品股份有限公司是一家主要从事研发、生产及销售医疗器械产品的中国公司。该公司通过六个分部运营业务。医疗器械产品分部生产及销售临床护理、医学检验、麻醉及手术相关产品以及其他耗材。骨科产品分部生产及销售骨科产品(包括组织修复产品线)。介入产品分部生产及销售肿瘤及血管介入器械。药品包装产品分部生产及销售预充式注射器及冲管注射器。血液管理产品分部生产及销售血液採集、辐射、贮存、分离及灭菌消毒产品。其他分部从事融资租赁及保理业务。该公司主要在中国国内和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"SHWGY","market":"US","secType":"STK","nameCN":"威高股份ADR","latestPrice":2.54,"timestamp":1765999800000,"preClose":2.54,"halted":0,"volume":0,"delay":15,"floatShares":605300150,"shares":1142658081,"eps":0.246606,"marketStatus":"交易中","change":0,"latestTime":"12-17 14:30:00 EST 延时","open":2.54,"high":2.54,"low":2.54,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.246606,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1766005200000},"marketStatusCode":2,"adr":0,"adrRate":4,"exchange":"PINK LIMITED","adjPreClose":2.54,"volumeRatio":0},"requestUrl":"/m/hq/s/SHWGY/tweets","defaultTab":"tweets","newsList":[{"id":"2583537677","title":"中泰国际:予威高股份“增持”评级 目标价5.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583537677","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583537677?lang=zh_cn&edition=full","pubTime":"2025-11-12 14:33","pubTimestamp":1762929193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中泰国际发布研报称,将威高股份目标价定为5.94港元,给予“增持”评级。股东净利润预测分别下调6.4%、5.4%、5.8%,但收入与利润均仍将实现正向增长。中泰国际主要观点如下:2025年前三季度收入实现正向增长公司2025年第三季度收入同比增加2.6%至32.6亿元,因此公司的前三季度收入同比增加0.9%至约98.1亿元,收入略逊预期,但实现正向增长。按目前情况,该行预计骨科业务的销售收入下半年将回暖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112143710a6f3b58d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112143710a6f3b58d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4198","SHWGY"],"gpt_icon":0},{"id":"2576854822","title":"大健康行业周报 |瑞普生物:1.54亿元加码宠物产业链布局;123亿,中东资本押注中国医械公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2576854822","media":"保观","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576854822?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:30","pubTimestamp":1760959832,"startTime":"0","endTime":"0","summary":"保观 |聚焦保险创新国内篇行业动态瑞普生物:1.54亿元加码宠物产业链布局瑞普生物拟联合三家专业投资机构,共同发起设立天津保瑞股权投资合伙企业,认缴出资总额4.06亿元,瑞普生物出资1.54亿元,专项投资宠物产业链相关标的公司,包括宠物医疗、食品、服务等。123亿,中东资本押注中国医械公司全球规模最大的主权财富基金之一的中东主权财富基金正加速拓展中国医疗健康领域投资版图。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020201007a46a2d15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020201007a46a2d15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06699","BK4198","01066","SHWGY"],"gpt_icon":0},{"id":"2557767555","title":"威高股份将于8月27日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2557767555","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557767555?lang=zh_cn&edition=full","pubTime":"2025-08-07 17:58","pubTimestamp":1754560712,"startTime":"0","endTime":"0","summary":"格隆汇8月7日丨威高股份(01066.HK)公告,董事会会议将于2025年8月27日举行,藉以(其中包括)考虑及批准公司及其附属公司截至2025年6月30日止六个月的未经审核中期业绩及其发布以及考虑派发中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807175845973966d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807175845973966d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1222","LU0287142896.SGD","01066","LU0173614495.USD","SHWGY","BK1589"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.weigaogroup.com","stockEarnings":[{"period":"1week","weight":0.0239},{"period":"1month","weight":0.0388},{"period":"3month","weight":0.1708},{"period":"6month","weight":0.1505},{"period":"1year","weight":0.1823},{"period":"ytd","weight":0.1311}],"description":"山东威高集团医用高分子制品股份有限公司是一家主要从事研发、生产及销售医疗器械产品的中国公司。该公司通过六个分部运营业务。医疗器械产品分部生产及销售临床护理、医学检验、麻醉及手术相关产品以及其他耗材。骨科产品分部生产及销售骨科产品(包括组织修复产品线)。介入产品分部生产及销售肿瘤及血管介入器械。药品包装产品分部生产及销售预充式注射器及冲管注射器。血液管理产品分部生产及销售血液採集、辐射、贮存、分离及灭菌消毒产品。其他分部从事融资租赁及保理业务。该公司主要在中国国内和海外市场开展业务。","exchange":"PINK LIMITED","name":"威高股份ADR","nameEN":"Shandong Weigao Group Medical Polymer Co., Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"威高股份ADR(SHWGY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供威高股份ADR(SHWGY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"威高股份ADR,SHWGY,威高股份ADR股票,威高股份ADR股票老虎,威高股份ADR股票老虎国际,威高股份ADR行情,威高股份ADR股票行情,威高股份ADR股价,威高股份ADR股市,威高股份ADR股票价格,威高股份ADR股票交易,威高股份ADR股票购买,威高股份ADR股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"威高股份ADR(SHWGY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供威高股份ADR(SHWGY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}